IL HB1102

Expands the definition of "at risk for ovarian cancer" to include individuals with high CA-125 levels indicated by blood test screening, in addition to those with family history or BRCA1/BRCA2 mutations

Broadens covered "surveillance tests for ovarian cancer" to include all medically viable detection methods such as ultrasounds, MRIs, x-rays, CT scans, and CA-125 blood tests

Replaces the previous limited annual screening requirement (CA-125 serum tumor marker testing, transvaginal ultrasound, and pelvic examination) with the expanded testing options

Requires group health insurance policies to cover these ovarian cancer surveillance tests without deductibles, copays, or other cost-sharing for at-risk individuals

Effective date: January 1, 2027